1-4 of 4
David C. Taussig
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1 -mutated AML

Clinical Trials & Observations
Stéphane de Botton, Pierre Fenaux, Karen Yee, Christian Récher, Andrew H. Wei, Pau Montesinos, David C. Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Montserrat Arnan, William Blum, Daniela Cilloni, Devendra K. Hiwase, Joseph G. Jurcic, Jürgen Krauter, Xavier Thomas, Justin M. Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jorge Cortes
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3117–3127.
https://doi.org/10.1182/bloodadvances.2022009411
Published: 2023
Includes: Supplemental data
Journal Articles

Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation

Harry J. Iland, Nigel Russell, Richard Dillon, Andre C. Schuh, Aditya Tedjaseputra, Andrew Wei, Asim Khwaja, Steven Knapper, Steven W. Lane, John Reynolds, Mary Frances McMullin, Annalise Martin, Peter Tan, David C. Taussig, Anny Wong, John Taper, Christina Fraga, Richard Kelly, Kiran Tawana, Priyanka Mehta, Alain Mina, Jessica K. Altman, Ingolf Mølle, Sudhir Tauro, Eleni Tholouli
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2580–2585.
https://doi.org/10.1182/bloodadvances.2022007126
Published: 2023
Includes: Supplemental data
Journal Articles

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

Clinical Trials & Observations
Amer M. Zeidan, Isaac Boss, C. L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa E. Hasle, Andrzej Hellmann, David C. Taussig, Mar Tormo, Maria Teresa Voso, James Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2219–2229.
https://doi.org/10.1182/bloodadvances.2021006138
Published: 2022
Includes: Supplemental data
Journal Articles

Quizartinib-resistant FLT3 -ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736

Andrew S. Moore, Amir Faisal, Grace W. Y. Mak, Farideh Miraki-Moud, Vassilios Bavetsias, Melanie Valenti, Gary Box, Albert Hallsworth, Alexis de Haven Brandon, Cristina P. R. Xavier, Randal Stronge, Andrew D. J. Pearson, Julian Blagg, Florence I. Raynaud, Rajesh Chopra, Suzanne A. Eccles, David C. Taussig, Spiros Linardopoulos
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1478–1491.
https://doi.org/10.1182/bloodadvances.2019000986
Published: 2020
Includes: Supplemental data